With the exception of one protein (LPL), there was no evidence of any drug development for two proteins, particularly PON3, which is highly expressed in liver cells and is a promising drug target for improved prevention and treatment of T2D. The gene discussed is LPL; the disease is type 2 diabetes mellitus.